The work at Epiomed Therapeutics Inc. dates back to NASA's efforts back in the 1980s to reduce motion sickness on the space shuttle, but the semivirtual biotech start-up has tweaked those early discoveries and set its sights on the multi-billion-dollar nausea and vomiting market.